When AT3ova cells were treated with MEKi, MHC-I expression was significantly upregulated (one-way ANOVA, P < 0.01) by cell intrinsic mechanisms on the tumor cells, potentially enhancing their ability to present antigen to CD8+ OT-I ovalbumin-specific T cells (Fig. 3a). The gene discussed is CD8A; the disease is neoplasm.